Adam JacksonJuly 12, 2023
Psyence stretched its fiscal runway and paid off all the debt on its balance sheet.
Tag: Filament Health
Adam JacksonJuly 12, 2023Adam JacksonJune 30, 2023
Filament is set to receive up to "seven figures" in milestone payments.
Debra BorchardtJune 14, 2023
Filament's CEO recently spoke with Executive Editor Debra Borchardt about the company's plans.
Debra BorchardtMay 16, 2023
Filament is actively pursuing partnerships for development and testing of its compounds.
Adam JacksonApril 3, 2023
The company made $364,500 in licensing revenues.
Dave HodesJanuary 4, 2023
Some analysts have called the industry's business model problematic.
Debra BorchardtDecember 15, 2022
Company also closed a C$3 million capital raise.
Dave HodesDecember 5, 2022
Scientific community looks for ways to effectively research psilocybin.
Dave HodesNovember 22, 2022
Even without revenue, psychedelics companies find financing for ongoing research.
Dave HodesAugust 16, 2022The emerging psychedelics industry is stuck with a sort of default business model that goes something like this: build a team of entrepreneurial-minded C-suite people, add a few qualified medical people, get a patented psychedelic molecule or compound to test and develop, build a research and development operation, then begin the clinical trials as quickly […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.